semaglutide cardiac protection Does Ozempic Help Your Heart? Truth About GLP-1s & Cardiovascular Risk Safety and Efficacy of Semaglutide

Wegovy is approved for weight loss, fatty liver disease, and cardiovascular risk reduction in people with obesity or overweight

The CagriSema amylin+GLP-1 combination achieves effects comparable to Retatrutide monotherapy, but Retatrutide has a stronger standalone effect (24 % in Phase 2)

Increase to 0.5 mg weekly for the next 4 weeks

Further Increases: Depending on the efficacy and tolerability, the dose can be increased to 10 mg once weekly after at least 4 weeks on the 5 mg dose, and potentially to 15 mg once weekly after at least another 4 weeks

Additionally, this is pretty interesting, researchers thought it was actually impossible to create a weight loss drug that was both safe and effective